BrainStorm Cell Therapeutics has appointed Peter J. Pitts, a former FDA Associate Commissioner, to its Board of Directors as the company prepares to start its Phase 3b ENDURANCE trial for its ALS therapy NurOwn. This trial is notable for being the first ALS therapeutic candidate to receive a Special Protocol Assessment from the FDA, signaling strong regulatory support. Pitts brings extensive regulatory expertise, which BrainStorm believes will help advance the trial and bring the therapy to patients faster. The company aims to leverage this leadership to navigate regulatory processes with urgency and scientific rigor for ALS treatment development.
Marvell Technology reported adjusted earnings of 80 cents per share, slightly above analyst estimates, with revenue rising 28% year-over-year to $2.42 billion. The company's data center segment, driven by AI infrastructure demand, hit a record $1.83 ...
Wall Street's recent rally is heavily reliant on a small group of mega-cap technology stocks like Nvidia, Apple, and Alphabet, driven by strong demand for AI-related products and investments. Analysts warn that this narrow market breadth, combined wi...
Trogenix has dosed the first patient in its Phase I/II ADePT trial testing TGX-007, a dual-payload gene therapy for glioblastoma, at sites in the UK and US. TGX-007 uses a proprietary Synthetic Super-Enhancer platform to selectively kill tumor cells ...
B2B ecommerce platform migrations typically succeed at launch but face revenue losses in the 30 to 90 days afterward due to failures in custom pricing rules, system integrations, and SEO ranking drops. These issues arise because post-launch monitorin...
Alamos Gold announced a quarterly dividend of $0.04 per share payable on June 25, 2026, to shareholders of record as of June 11, 2026. The company has repurchased 753,600 shares at a cost of $30 million in May 2026 under its Normal Course Issuer Bid....
